Here is how GLP-1 options compare, according to clinical trials: Daily oral semaglutide (Wegovy): Average weight loss of 13.6 percent of body weight after about 15 months of treatment, compared with 2.2 percent in a placebo group Average weight loss of 11.2 percent of body weight after 72 weeks of treatment, compared with 2.1 percent in the placebo group
While these findings offer reassurance in cases of inadvertent exposure to GLP-1 medications during the first trimester of pregnancy, larger trials are needed for more conclusive results
Physicians who testified at the hearing described patients continuing to use the peptide, now sourced from unregulated online sellers rather than pharmacies
His expertise spans cosmetic dermatology, focusing on injectable neuromodulators like Botox, Daxxify, Dysport, and Xeomin, alongside an array of fillers including RHA, Juvederm, and Sculptra, to name a few